Lycia Therapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €34.3M of shares over the last 90 days, the latest by Venrock Healthcare Capital Partners III, L.P., filed 04 Nov 2026.
Lycia Therapeutics, Inc.: what insiders have been doing
Lycia Therapeutics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 5 November 2025 and 5 November 2026, 2 insiders published 15 filings.
The flow runs one way only: 1 insider bought (12 purchases totalling €34.3M) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €31.2M, the purchase published on 27 October 2026 by Venrock Healthcare Capital Partners III, L.P. is the largest of the period. The buyers include 1 major shareholder.
For context, the typical company on the same exchange (median of 3,180 companies) published 24 filings over the same period, against 15 filings here. Looking back to 2026, when coverage begins, insiders filed 12 purchases and no sales.
The most recent open-market purchase was published on 4 November 2026, 5 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 8,305 shares@ US$26.95Common StockSEC:0001231919-26-001536:0Canonical exit: 31 Jan 2027 (T+90)
- 10,570 shares@ US$25.230.019% mcap0.7% of flowCommon StockSEC:0001231919-26-001519:0Canonical exit: 26 Jan 2027 (T+90)
- 4,430 shares@ US$25.970.0080% mcap0.3% of flowCommon StockSEC:0001231919-26-001519:1Canonical exit: 26 Jan 2027 (T+90)
- 1,000 shares@ US$26.330.0018% mcap0.1% of flowCommon StockSEC:0001231919-26-001519:2Canonical exit: 27 Jan 2027 (T+90)
- 8,804 shares@ US$26.270.016% mcap0.6% of flowCommon StockSEC:0001231919-26-001519:3Canonical exit: 28 Jan 2027 (T+90)
- 200 shares@ US$26.860.0004% mcap0.0% of flowCommon StockSEC:0001231919-26-001519:4Canonical exit: 28 Jan 2027 (T+90)
- 5,631,425 sharesCommon StockSEC:0001193125-26-436415:0
- 1,393,882 sharesCommon StockSEC:0001193125-26-436415:1
- 4,779,793 sharesCommon StockSEC:0001231919-26-001503:2
- 24,560 shares@ US$25.681.7% of flowCommon StockSEC:0001231919-26-001503:0Canonical exit: 21 Jan 2027 (T+90)
- 28,379 shares@ US$26.112.0% of flowCommon StockSEC:0001231919-26-001503:1Canonical exit: 21 Jan 2027 (T+90)
- 1,944,444 shares@ US$18.0092.9% of flowCommon StockSEC:0001231919-26-001503:3Canonical exit: 24 Jan 2027 (T+90)
- 8,261 shares@ US$26.970.6% of flowCommon StockSEC:0001231919-26-001503:4Canonical exit: 24 Jan 2027 (T+90)
- 8,729 shares@ US$25.840.6% of flowCommon StockSEC:0001231919-26-001503:5Canonical exit: 25 Jan 2027 (T+90)
- 31,067 shares@ US$26.842.2% of flowCommon StockSEC:0001231919-26-001503:6Canonical exit: 25 Jan 2027 (T+90)
15 of 15 declarations
About Lycia Therapeutics, Inc.
Lycia Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. It utilizes a unique technology platform to design drugs targeting specific proteins.
